Basic Information
| LncRNA/CircRNA Name | CTA |
| Synonyms | NA |
| Region | GRCh38_8:56074592-56075274 |
| Ensemble | ENSG00000253603 |
| Refseq | NR_149110 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | doxorubicin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, MIT, Luciferase reporter assays |
| Sample | osteosarcoma tissues, cell lines (Saos-2, U-2OS and MG-63) |
| Expression Pattern | down-regulated |
| Function Description | Our data showed that lncRNA CTA was markedly downregulated in OS tissues compared to their matched non-tumor tissues. In addition, OS patients with low lncRNA CTA levels showed a worse prognosis when compared with those with high expression of lncRNA CTA. LncRNA CTA could be activated by doxorubicin (DOX), and could promote OS cell apoptosis by competitively binding miR-210, while inhibit cell autophagy. |
| Pubmed ID | 28415557 |
| Year | 2017 |
| Title | Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy |
External Links
| Links for CTA | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |